Flagship Biosciences presents quantitative diagnostic antibody development process at Protein Science Week
Palm Springs, CA – Jan. 14, 2014 – Flagship presented an in-depth look at companion diagnostic development at Protein Science Week. The presentation, Immunohistochemistry Based Companion Diagnostic Strategies for Antibody Drug Conjugates, covered Flagship Bioscience’s novel approach to developing assays and biomarkers in conjunction with a CDx for patient selection.
The need for the well timed development of a companion diagnostic assay is well understood by Flagship’s team of expert scientists and engineers. Improper timeline alignment in the drug development and companion diagnostic development process can mean added cost and delays to pharmaceutical researchers. Sophisticated analysis of IHC, as provided by Flagship, provides advanced solutions to this kind of research.
The IHC CDx ADC presentation covered the necessary components of a successful companion diagnostic assay, common misconceptions about their development, factors affecting antibody drug conjugate response, and strategic insights on patient selection planning. Examples were provided to detail aspects of IHC staining and tissue analysis that are important in understanding antibody drug conjugate response data. Approaches for integrating and leveraging therapeutic antibody development expertise at pharmaceutical companies into diagnostic FFPE design approaches were also discussed.
